Compare $NPCE vs $SGHT | Chartloom

Compare

$NPCE vs $SGHT

Neuropace Inc · Sight Sciences Inc

NPCE

Neuropace Inc

SGHT

Sight Sciences Inc

Compare $NPCE vs $SGHT

Comparing Neuropace Inc and Sight Sciences Inc

NPCENeuropace Inc

SGHTSight Sciences Inc

NPCENeuropace Inc

Market cap

$432M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.83x

Rev growth (TTM)

11.6%

YTD performance

-16.5%

52W performance

13.8%

FCF yield

-2.7%

SGHTSight Sciences Inc

Market cap

$484M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.94x

Rev growth (TTM)

9.3%

YTD performance

18.9%

52W performance

156.2%

FCF yield

-4.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NPCE

SGHT

Detailed metrics comparison

NPCE

Neuropace Inc

SGHT

Sight Sciences Inc

Market Cap

NPCE$432M

SGHT$484M

Enterprise Value

NPCE$478M

SGHT$445M

Price

NPCE$12.67

SGHT$8.89

P/E Ratio

NPCEN/A

SGHTN/A

P/S Ratio

NPCE4.37x

SGHT5.80x

EV/Sales

NPCE4.84x

SGHT5.33x

EV/EBITDA

NPCE0.00x

SGHT0.00x

P/B Ratio

NPCE36.68x

SGHT8.88x

P/FCF Ratio

NPCEN/A

SGHTN/A

EV/FCF

NPCE-41.21x

SGHT-18.81x

PEG Ratio

NPCEN/A

SGHTN/A

Forward P/E (NTM)

NPCEN/A

SGHTN/A

Forward P/S (NTM)

NPCE3.83x

SGHT4.94x

Revenue (TTM)

NPCE$99M

SGHT$83M

Revenue Growth (YoY)

NPCE11.6%

SGHT9.3%

Forward Rev Growth

NPCE22.0%

SGHT11.9%

Gross Margin (TTM)

NPCE79.6%

SGHT88.4%

Operating Margin (TTM)

NPCE0.0%

SGHT0.0%

EBITDA Margin (TTM)

NPCE-15.0%

SGHT-32.5%

Net Margin (TTM)

NPCE-19.3%

SGHT-35.7%

FCF Margin (TTM)

NPCE-11.7%

SGHT-28.4%

Net Income (TTM)

NPCE$-19M

SGHT$-30M

FCF (TTM)

NPCE$-12M

SGHT$-24M

EPS (TTM)

NPCE-$0.56

SGHT-$0.55

ROE (TTM)

NPCE-11968.0%

SGHT-5064.0%

ROA (TTM)

NPCE-1871.0%

SGHT-2668.0%

ROIC (TTM)

NPCE-2552.0%

SGHT-3000.0%

Cash

NPCE$13M

SGHT$80M

Debt

NPCE$59M

SGHT$41M

Net Cash/Debt

NPCE$-46M

SGHT$39M

Current Ratio (TTM)

NPCE4.94x

SGHT4.95x

Quick Ratio (TTM)

NPCE3.82x

SGHT4.45x

Debt/Equity (TTM)

NPCE4.97x

SGHT0.77x

Debt/Assets (TTM)

NPCE0.0%

SGHT0.0%

Interest Coverage (TTM)

NPCEN/A

SGHTN/A

Net Debt/EBITDA (TTM)

NPCE0.00x

SGHT0.00x

Beta

NPCE1.95

SGHT2.45

52W Performance

NPCE13.8%

SGHT156.2%

YTD Performance

NPCE-16.5%

SGHT18.9%

% from 52W High

NPCE-35.4%

SGHT-8.5%

% from 52W Low

NPCE37.4%

SGHT178.7%

Asset Turnover (TTM)

NPCE0.97x

SGHT0.75x

FCF Yield (TTM)

NPCE-2.7%

SGHT-4.9%

Earnings Yield (TTM)

NPCE-4.4%

SGHT-6.2%

Dividend Yield (TTM)

NPCEN/A

SGHTN/A

Rule of 40

NPCE-0.2

SGHT-19.1

EV/GP/RG

NPCE0.40

SGHT0.34

Ticker research

View NPCE research View SGHT research

Metric	NPCE Neuropace Inc	SGHT Sight Sciences Inc
Market & Valuation
Market Cap	$432M	$484M
Enterprise Value	$478M	$445M
Price	$12.67	$8.89
P/E Ratio	N/A	N/A
P/S Ratio	4.37x	5.80x
EV/Sales	4.84x	5.33x
EV/EBITDA	0.00x	0.00x
P/B Ratio	36.68x	8.88x
P/FCF Ratio	N/A	N/A
EV/FCF	-41.21x	-18.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.83x	4.94x
Revenue & Growth
Revenue (TTM)	$99M	$83M
Revenue Growth (YoY)	11.6%	9.3%
Forward Rev Growth	22.0%	11.9%
Profitability
Gross Margin (TTM)	79.6%	88.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-15.0%	-32.5%
Net Margin (TTM)	-19.3%	-35.7%
FCF Margin (TTM)	-11.7%	-28.4%
Net Income (TTM)	$-19M	$-30M
FCF (TTM)	$-12M	$-24M
EPS (TTM)	-$0.56	-$0.55
ROE (TTM)	-11968.0%	-5064.0%
ROA (TTM)	-1871.0%	-2668.0%
ROIC (TTM)	-2552.0%	-3000.0%
Financial Health
Cash	$13M	$80M
Debt	$59M	$41M
Net Cash/Debt	$-46M	$39M
Current Ratio (TTM)	4.94x	4.95x
Quick Ratio (TTM)	3.82x	4.45x
Debt/Equity (TTM)	4.97x	0.77x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.95	2.45
52W Performance	13.8%	156.2%
YTD Performance	-16.5%	18.9%
% from 52W High	-35.4%	-8.5%
% from 52W Low	37.4%	178.7%
Efficiency & Yields
Asset Turnover (TTM)	0.97x	0.75x
FCF Yield (TTM)	-2.7%	-4.9%
Earnings Yield (TTM)	-4.4%	-6.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-0.2	-19.1
EV/GP/RG	0.40	0.34
Ticker research	View NPCE research	View SGHT research

Valuation

P/S Ratio

NPCE

4.37x

SGHT

5.80x

EV/FCF

NPCE

-41.21x

SGHT

-18.81x

Growth & revenue

Revenue Growth TTM

NPCE

11.6%

SGHT

9.3%

Forward Revenue Growth

NPCE

22.0%

SGHT

11.9%

Profitability & performance

Gross Margin

SGHT

88.4%

NPCE

79.6%

ROE

SGHT

-5064.0%

NPCE

-11968.0%

FCF Yield %

NPCE

-2.7%

SGHT

-4.9%

52-Week Performance

SGHT

156.2%

NPCE

13.8%

Detailed metrics comparison

NPCE

Neuropace Inc

SGHT

Sight Sciences Inc

Market Cap

NPCE$432M

SGHT$484M

Enterprise Value

NPCE$478M

SGHT$445M

Price

NPCE$12.67

SGHT$8.89

P/E Ratio

NPCEN/A

SGHTN/A

P/S Ratio

NPCE4.37x

SGHT5.80x

EV/Sales

NPCE4.84x

SGHT5.33x

EV/EBITDA

NPCE0.00x

SGHT0.00x

P/B Ratio

NPCE36.68x

SGHT8.88x

P/FCF Ratio

NPCEN/A

SGHTN/A

EV/FCF

NPCE-41.21x

SGHT-18.81x

PEG Ratio

NPCEN/A

SGHTN/A

Forward P/E (NTM)

NPCEN/A

SGHTN/A

Forward P/S (NTM)

NPCE3.83x

SGHT4.94x

Revenue (TTM)

NPCE$99M

SGHT$83M

Revenue Growth (YoY)

NPCE11.6%

SGHT9.3%

Forward Rev Growth

NPCE22.0%

SGHT11.9%

Gross Margin (TTM)

NPCE79.6%

SGHT88.4%

Operating Margin (TTM)

NPCE0.0%

SGHT0.0%

EBITDA Margin (TTM)

NPCE-15.0%

SGHT-32.5%

Net Margin (TTM)

NPCE-19.3%

SGHT-35.7%

FCF Margin (TTM)

NPCE-11.7%

SGHT-28.4%

Net Income (TTM)

NPCE$-19M

SGHT$-30M

FCF (TTM)

NPCE$-12M

SGHT$-24M

EPS (TTM)

NPCE-$0.56

SGHT-$0.55

ROE (TTM)

NPCE-11968.0%

SGHT-5064.0%

ROA (TTM)

NPCE-1871.0%

SGHT-2668.0%

ROIC (TTM)

NPCE-2552.0%

SGHT-3000.0%

Cash

NPCE$13M

SGHT$80M

Debt

NPCE$59M

SGHT$41M

Net Cash/Debt

NPCE$-46M

SGHT$39M

Current Ratio (TTM)

NPCE4.94x

SGHT4.95x

Quick Ratio (TTM)

NPCE3.82x

SGHT4.45x

Debt/Equity (TTM)

NPCE4.97x

SGHT0.77x

Debt/Assets (TTM)

NPCE0.0%

SGHT0.0%

Interest Coverage (TTM)

NPCEN/A

SGHTN/A

Net Debt/EBITDA (TTM)

NPCE0.00x

SGHT0.00x

Beta

NPCE1.95

SGHT2.45

52W Performance

NPCE13.8%

SGHT156.2%

YTD Performance

NPCE-16.5%

SGHT18.9%

% from 52W High

NPCE-35.4%

SGHT-8.5%

% from 52W Low

NPCE37.4%

SGHT178.7%

Asset Turnover (TTM)

NPCE0.97x

SGHT0.75x

FCF Yield (TTM)

NPCE-2.7%

SGHT-4.9%

Earnings Yield (TTM)

NPCE-4.4%

SGHT-6.2%

Dividend Yield (TTM)

NPCEN/A

SGHTN/A

Rule of 40

NPCE-0.2

SGHT-19.1

EV/GP/RG

NPCE0.40

SGHT0.34

Ticker research

View NPCE research View SGHT research

Metric	NPCE Neuropace Inc	SGHT Sight Sciences Inc
Market & Valuation
Market Cap	$432M	$484M
Enterprise Value	$478M	$445M
Price	$12.67	$8.89
P/E Ratio	N/A	N/A
P/S Ratio	4.37x	5.80x
EV/Sales	4.84x	5.33x
EV/EBITDA	0.00x	0.00x
P/B Ratio	36.68x	8.88x
P/FCF Ratio	N/A	N/A
EV/FCF	-41.21x	-18.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.83x	4.94x
Revenue & Growth
Revenue (TTM)	$99M	$83M
Revenue Growth (YoY)	11.6%	9.3%
Forward Rev Growth	22.0%	11.9%
Profitability
Gross Margin (TTM)	79.6%	88.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-15.0%	-32.5%
Net Margin (TTM)	-19.3%	-35.7%
FCF Margin (TTM)	-11.7%	-28.4%
Net Income (TTM)	$-19M	$-30M
FCF (TTM)	$-12M	$-24M
EPS (TTM)	-$0.56	-$0.55
ROE (TTM)	-11968.0%	-5064.0%
ROA (TTM)	-1871.0%	-2668.0%
ROIC (TTM)	-2552.0%	-3000.0%
Financial Health
Cash	$13M	$80M
Debt	$59M	$41M
Net Cash/Debt	$-46M	$39M
Current Ratio (TTM)	4.94x	4.95x
Quick Ratio (TTM)	3.82x	4.45x
Debt/Equity (TTM)	4.97x	0.77x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.95	2.45
52W Performance	13.8%	156.2%
YTD Performance	-16.5%	18.9%
% from 52W High	-35.4%	-8.5%
% from 52W Low	37.4%	178.7%
Efficiency & Yields
Asset Turnover (TTM)	0.97x	0.75x
FCF Yield (TTM)	-2.7%	-4.9%
Earnings Yield (TTM)	-4.4%	-6.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-0.2	-19.1
EV/GP/RG	0.40	0.34
Ticker research	View NPCE research	View SGHT research